Xalatan and Chromatopsia - a phase IV clinical study of FDA data

Summary:

Chromatopsia is reported as a side effect among people who take Xalatan (latanoprost), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Azopt, and have Ill-defined disorder.

The phase IV clinical study analyzes which people have Chromatopsia when taking Xalatan. It is created by eHealthMe based on reports of 25,196 people who have side effects when taking Xalatan from the FDA, and is updated regularly.

What is Xalatan?

Xalatan has active ingredients of latanoprost. It is often used in glaucoma. eHealthMe is studying from 25,550 Xalatan users. Check the latest studies of Xalatan.

What is Chromatopsia?

Chromatopsia (visual defect in which colourless objects appear to be tinged with colour) is found to be associated with 145 drugs and 324 conditions by eHealthMe. Check the latest studies of Chromatopsia.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

25,196 people reported to have side effects when taking Xalatan.
Among them, 18 people (0.07%) have Chromatopsia.

Among these 18 people:

How long have people been on Xalatan when they have Chromatopsia? *

What is the gender of people who have Chromatopsia when taking Xalatan? *

female: 66.67 %
male: 33.33 %

What is the age of people who have Chromatopsia when taking Xalatan? *

What are other drugs people take besides Xalatan? *

What are other side effects people have besides Chromatopsia? *

Drug Ineffective: 5 people, 27.78%
Visual Acuity Reduced (reduced clearness of vision): 5 people, 27.78%
Chest Pain: 4 people, 22.22%
Cough: 4 people, 22.22%
Intraocular Pressure Increased: 3 people, 16.67%
Fall: 3 people, 16.67%
Headache (pain in head): 3 people, 16.67%
Vision Blurred: 3 people, 16.67%
Visual Impairment: 3 people, 16.67%
Intervertebral Disc Protrusion (spinal disc protrusion): 2 people, 11.11%

What are the existing conditions these people have? *

Ill-Defined Disorder: 2 people, 11.11%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 5.56%
Fluid Retention (an abnormal accumulation of fluid in the blood): 1 person, 5.56%
Atopy (a genetic disposition to develop an allergic reaction): 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Xalatan and have Chromatopsia?

- Check whether Chromatopsia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Xalatan:

Xalatan (25,550 reports)

Chromatopsia treatments and more:

Chromatopsia (1,099 reports)

Browse all side effects of Xalatan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Chromatopsia:

Chromatopsia (145 drugs)

Browse all the conditions that are associated with Chromatopsia:

Chromatopsia (324 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on latanoprost (the active ingredients of Xalatan) and Xalatan (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.